Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial

We have studied a three drug combination with bortezomib, cyclophosphamide and dexamethasone (CyBorD) on a 28 day cycle in the treatment of newly diagnosed multiple myeloma patients to assess response and toxicity. The primary endpoint of response was evaluated after four cycles. Thirty-three newly...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Reeder, Craig B., Reece, Donna E., Kukreti, Vishal, Chen, Christine, Trudel, Suzanne, Hentz, Joseph, Noble, Brie, Pirooz, Nicholas A., Spong, Jacy E., Piza, Jesus G., Zepeda, Victor H. Jimenez, Mikhael, Joseph R., Leis, Jose F., Bergsagel, P. Leif, Fonseca, Rafael, Stewart, A. Keith
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2711213/
https://ncbi.nlm.nih.gov/pubmed/19225538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2009.26
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky